| 143.29 80.33 (127.59%) | 08-19 12:20 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 190.93 |
1-year : | 223 |
| Resists | First : | 163.47 |
Second : | 190.93 |
| Pivot price | 64.99 |
|||
| Supports | First : | 94.98 |
Second : | 52.65 |
| MAs | MA(5) : | 79.33 |
MA(20) : | 62.59 |
| MA(100) : | 56.45 |
MA(250) : | 43.12 |
|
| MACD | MACD : | 7 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 84.3  |
D(3) : | 85.7 |
| RSI | RSI(14): 89.7 |
|||
| 52-week | High : | 163.47 | Low : | 22.28 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ MRNA ] has closed It is unclear right now based on current values. 430.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 64.45 - 64.76 | 64.76 - 65.07 |
| Low: | 61.22 - 61.6 | 61.6 - 61.99 |
| Close: | 62.23 - 62.86 | 62.86 - 63.47 |
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Wed, 19 Aug 2026
Moderna short-sellers stare at record one-day loss as shares surge on vaccine data - reuters.com
Wed, 19 Aug 2026
Moderna Stock's Best Day Ever After Cancer Trial Win - Moderna (NASDAQ:MRNA) - Benzinga
Wed, 19 Aug 2026
Moderna and Merck Say mRNA Vaccine Prevents Melanoma From Returning - nytimes.com
Wed, 19 Aug 2026
Moderna stock price is skyrocketing on mRNA cancer vaccine trial news: Here's what's happening - Fast Company
Wed, 19 Aug 2026
Moderna Shares Double on Success of mRNA Cancer Vaccine - wsj.com
Wed, 19 Aug 2026
Moderna Stock Eyes Best Day Ever After Cancer Vaccine Breakthrough - Schaeffer's Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 399 (M) |
| Shares Float | 372 (M) |
| Held by Insiders | 7.2 (%) |
| Held by Institutions | 78.4 (%) |
| Shares Short | 52,400 (K) |
| Shares Short P.Month | 58,660 (K) |
| EPS | -7.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.94 |
| Profit Margin | -141.5 % |
| Operating Margin | -558 % |
| Return on Assets (ttm) | -13.3 % |
| Return on Equity (ttm) | -39 % |
| Qtrly Rev. Growth | 2 % |
| Gross Profit (p.s.) | -3.69 |
| Sales Per Share | 5.58 |
| EBITDA (p.s.) | -5.52 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1,070 (M) |
| Levered Free Cash Flow | 299 (M) |
| PE Ratio | -17.83 |
| PEG Ratio | 0 |
| Price to Book value | 8.39 |
| Price to Sales | 25.47 |
| Price to Cash Flow | -53.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|